Genea Board of Directors
The Genea Board comprises a group of very experienced business professionals and doctors with extensive backgrounds in a range of financial and healthcare fields.
The Board is accountable to the Company’s shareholders for its performance.
Dr Robert Woolcott
Co-Chairman, Genea Board
Robert joined the Genea Board as a Non-Executive Director of Genea Limited in January 2011. He was elected joint Chairman of the Board in September 2019.
He is Chairman of the Medical Practice Committee, a member of the Audit Committee, the Risk and Compliance Committee and the Remuneration and Nominations Committee. He is Medical and Management Director of Genea Newcastle and Chief Medical Officer of Genea Biomedx.
Robert graduated as a Bachelor of Medicine/Bachelor of Surgery with honours in 1981 and has 33 years of experience in IVF and reproductive microsurgery. He undertook the Advanced Management Program at Harvard Business School in 2007.
He is a former member of the RANZCOG Reproductive Endocrinology and Infertility subspecialist sub-committee, the Hunter Post Graduate Medical Institute Board and the Mayne Health Medical Advisory Board.
Ka King (Eric) Cheng
Co-Chairman, Genea Board
Aldworth Equity Management Limited Founding Partner
Eric joined the Genea Board as an Executive Director in December 2018. He was elected joint Chairman of the Board in September 2019.
Eric is the Founding Partner of Aldworth Equity Management Limited and has over 28 years of experience in the banking industry with geographic coverage over China, Hong Kong, Macau and SE Asia. He has worked in various senior postings for BNP Paribas, Credit Suisse, USB, Standard Chartered Bank and HSBC.
Eric graduated in 1990 with a Bachelor of Business Studies and obtained a Master of Finance from City University of Hong Kong.
Tat Joel Chang
Mason Group Holdings Chief Operating Officer
Joel joined the Genea Board as a Non-Executive Director in January 2019.
Joel has considerable strategic, financial and advisory experience. He is the co- founder of AID Partners Capital Limited and a founder of Genius Link Assets Management Limited, both are private equity investment companies. He is an investment committee member of AID Partners Capital Limited, and is responsible for its strategic investment planning. Prior to founding AID Partners Capital Limited, he was the chief investment officer of Investec Asia Limited, a managing director of China Everbright Capital Limited and an executive director of BNP Prime Peregrine Capital Limited. He is also a member of the Australian Society of Certified Practicing Accountants and the Hong Kong Institute of Certified Public Accountants.
He obtained a Bachelor of Economics from Monash University in 1990. Mr. Chang is an independent non-executive director of OCI International Holdings Limited , and an independent non-executive director of Hailiang International Holdings Limited. He was formerly a non-executive director of AID Partners Technology Holdings Limited, a non-executive director of Kong Sun Holdings Ltd., an independent non-executive director of Kingsoft Corporation Limited, and was an executive director and the chief financial officer of Orange Sky Golden Harvest Entertainment (Holdings) Limited. He was an independent director of China MobileGames and Entertainment Group Limited, a company previously listed on NASDAQ.
Wing Kei (Chapman) Chan
Mason Group Holdings Managing Director
Chapman joined the Genea Board as an Executive Director in December 2018.
Chapman has more than 10 years of private equity and investment banking experience in both Asia and the United States. His significant achievements include the US$115m buyout of a leading retailer in mother & baby products in China, the US$35m buyout of the largest IVF clinic group in Hong Kong, a RMB2bn Pre-IPO investment in Focus Media and the US$200m IPO of Dynam Japan. Chapman is a founding member of CMBC International and a former member of Piper Jaffray IBD. He earned a Bachelor of Science at the Chinese University of Hong Kong. He is a CFA Charter holder.
Hoi Kwong (Eddie) Hon
Aldworth Equity Management Limited Partner and Chief Operating Officer
Eddie joined the Genea Board as an Executive Director in January 2019.
Eddie is the Partner and COO of Aldworth Equity Management Limited. He has over 20 years of experience in finance, banking, operations and business development. He has also previously held various senior positions in listed and multinational companies.
Eddie graduated with a Bachelor of Economics from the University of Hong Kong in 1996 achieved an MBA from the University of South Australia in 2014.
Jeff Hungche Chen
Fullerton Health Group Chief Innovation Officer and Head of Capital Markets
Jeff joined the Genea Board as a Non-Executive Director in January 2019.
Prior to his current role at Fullerton Health, Jeff served as the Chief Strategy Officer of WeDoctor, overseeing capital markets strategy, strategic investment and cooperation and international business expansion. Prior to that, he was the Head of Technology Investment Banking for Asia Pacific at HSBC, where he was in charge and led all the TMT transactions across the region. Before joining HSBC, Jeff was a Senior Director with Credit Suisse Hong Kong’s TMT investment banking team. His coverage focused on capital raising for internet companies and high-profile traditional technology M&A transactions across Asia Pacific.
Jeff graduated from the University of Southern California in 2003 with a Bachelor of Science in Business Administration.
Dr Tomas Stojanov
Genea Chief Executive Officer
Tomas was appointed Genea Chief Executive Officer in January 2011 and joined the Genea Board as an Executive Director at the same time.
With more than 26 years of experience in the health, biotechnology and agriculture sectors in a range of capacities, Tomas has conducted scientific research and has worked in operational management and commercialisation roles. Immediately prior to his appointment as CEO of Genea, Tomas was Director of Research and General Manager of Stem Cells and Research.